Celyad Competitors and Similar CompaniesClear all
Celyad's competitors and similar companies include Alnylam.
 Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | |
Founding Date | Founding Date 2007 | Founding Date 2002 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Mont-Saint-Guibert, BE HQ New York, US | |
Employees | Employees 17 | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 11.8 m | Valuation ($) 36.5 b |
Financial | ||
Revenue (est.) | Revenue (est.) €21k (FY, 2025) | Revenue (est.) $3.7b (FY, 2025) |
Cost of goods | Cost of goods €8k (FY, 2025) | Cost of goods $677.2m (FY, 2025) |
Gross profit | Gross profit €5.9m (FY, 2025) | Gross profit $3b (FY, 2025) |
Net income | Net income €830k (FY, 2025) | Net income $313.7m (FY, 2025) |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company